0JJMBioPorto A/S
1.205DKKMkt Cap: —P/E: —Today
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and …
Industry Peers
Biotechnology$141.42BUSDP/E 32.5
$86.84BUSDP/E 20.9
$65.51BUSDP/E 40.1
$60.40BUSDP/E 39.5
$59.43BUSD
$43.65BUSDP/E 18.6
$45.20BUSD
$41.03BUSDP/E 64.6
$36.91BUSDP/E 34.3
$35.39BUSDP/E 46.0
$27.66BUSD
$25.95BUSDP/E 16.3
$25.84BUSD
$24.86BUSD
$21.15BUSDP/E 27.1
$19.66BUSDP/E 26.6
$17.78BUSDP/E 20.9
$16.07BUSDP/E 17.0
$14.74BUSD
$14.65BUSDP/E 18.6
Key Statistics
Company
Market Cap—
Enterprise Value73.87M $
Revenue (TTM)5.87M $
Gross Profit4.43M $
Net Income (TTM)-11.96M $
Revenue/Share0.0109 USD
Last Price1.205 DKK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees46
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-6.53
EV/Revenue12.59
P/S—
P/B8.82
EPS (TTM)-0.21
EPS (Forward)—
52W Range
—
52W High1.205 DKK
52W Low1.205 DKK
Profitability
Gross Margin75.44%
Oper. Margin-107.49%
EBITDA Margin-192.72%
Profit Margin-203.83%
ROE-125.60%
ROA-51.80%
Growth
Revenue Growth47.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-11.22M $
CapEx (TTM)—
FCF Margin-114.23%
FCF Yield—
Net Debt-6.90M $
Net Debt/EBITDA0.61
Balance Sheet
Debt/Equity11.94
Current Ratio3.25
Quick Ratio2.81
Book Value/Sh0.1270 DKK
Cash/Share0.1110 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 DKK
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float458.86M
Insiders29.80%
Institutions6.28%
Technical
SMA 502.151 (-44.0%)
SMA 2002.017 (-40.3%)
Beta1.38
S&P 52W Chg21.00%
Avg Vol (30d)1.92K
Avg Vol (10d)8.40K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—